Arbutus Biopharma (ABUS US): Synthetic Expert Call Transcript (18 Sep 2026)
Tender Offer Alignment: The $230 million modified Dutch auction tender offer (priced at $5.00 to $5.75 per share, expiring September 29, 2026) is...
98 Views
𝛼SK or SearchENTITY
Arbutus Biopharma (ABUS US)
Arbutus Biopharma (ABUS US)
2
Analysis
Health Care • United States
Arbutus Biopharma Corporation operates as a biopharmaceutical company. The Company specializes in discovering, developing, and commercializing a portfolio of drug candidates for patients suffering from chronic hepatitis B infection. Arbutus Biopharma serves patients and customers in Canada.
morex